TrialCancer medicine2020

Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.

Ying Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.